CLSD - クリアサイド・バイオメディカル (Clearside Biomedical Inc.) クリアサイド・バイオメディカル

 CLSDのチャート


 CLSDの企業情報

symbol CLSD
会社名 Clearside Biomedical Inc (クリアサイド・バイオメディカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クリアサイド・バイオメディカル(Clearside Biomedical Inc.)は目のまばゆい病気を治療するための業界初の薬物療法を開発している臨床生物医薬品会社である。同社の製品候補は、網膜に影響を及ぼす病気に重点を置く。網膜は、目の内部を覆う組織であり、主に視力の原因である。網膜に隣接する層である脈絡膜は、網膜に血液、酸素、栄養を供給する。そのマイクロインジェクターでは、脈絡膜と強膜と呼ばれる眼の外側保護層との間に位置する脈絡膜上腔(SCS)内に薬物が注入されて広がる。脈絡膜上皮の注射では、眼の中心部を占めるゼリー様物質である硝子体への薬物の注射など、他の眼内薬物投与技術と比較して、その脈絡膜の生成物候補が網膜および脈絡膜に直接的に投与される。   クリアサイド・バイオメディカルは米国のバイオ医薬品企業。後期臨床段階で、主に眼科疾患のための薬物送達技術の開発に焦点を当てる。同社の登録商標製品である「SCSマイクロインジェクタ―」は網膜と、黄斑浮腫を伴う病気に関連する脈絡膜を治療するために使用される。本社はジョ―ジア州アルファレッタ。   
本社所在地 900 North Point Parkway Suite 200 Alpharetta GA 30005 USA
代表者氏名 Christy L. Shaffer Christy L. Shaffer
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 678-270-3631
設立年月日 40664
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数
url www.clearsidebio.com
nasdaq_url https://www.nasdaq.com/symbol/clsd
adr_tso
EBITDA EBITDA(百万ドル) -71.68200
終値(lastsale) 5.8001
時価総額(marketcap) 185743695.8223
時価総額 時価総額(百万ドル) 185.10000
売上高 売上高(百万ドル) 0.21000
企業価値(EV) 企業価値(EV)(百万ドル) 110.51800
当期純利益 当期純利益(百万ドル) -72.13700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clearside Biomedical Inc revenues decreased from $135K to $0K. Net loss increased 55% to $37.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 62% to $29.8M (expense) General and administrative increase of 27% to $5.2M (expense).

 CLSDのテクニカル分析


 CLSDのニュース

   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   41 Stocks Moving in Tuesday's Pre-Market Session  2020/11/17 11:59:06 Benzinga
Gainers Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares rose 62.8% to $2.10 in pre-market trading as the company disclosed that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 31.6% to $2.21 in pre-market trading after the company’s 10% owner Bradford T Whitmore reported the purchase of 62,000 shares at an average price of $1.69 per share. Yunhong CTI Ltd. (NASDAQ: CTIB ) rose 27.1% to $2.30 in pre-market trading. Sequential Brands Group, Inc. (NASDAQ: SQBG ) rose 23.4% to $8.70 in pre-market trading after the company swung to a profit in the third quarter. Sequans Communications S.A. (NYSE: SQNS ) rose 15.8% to $5.34 in pre-market trading after gaining around 5% on Monday. Golden Bull Limited (NASDAQ: BTBT ) rose 13.5% to $6.14 in pre-market trading after jumping 25% on Monday. Tesla, Inc. (NASDAQ: TSLA ) rose 11.8% to $456.14 in pre-market trading. Tesla will be added to the S&P 500 index after months and months of speculation.
   Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update  2020/11/10 21:05:00 GlobeNewswire
- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2…
   Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Buy at Zacks Investment Research  2020/10/22 05:14:48 Zolmax News
Clearside Biomedical (NASDAQ:CLSD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $1.75 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 22.38% from the company’s current price. According to Zacks, […]
   The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September  2020/08/11 12:20:27 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical readout) Silk Road Medical Inc (NASDAQ: SILK ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) (announced FDA nod for pain drug) Unity Biotechnology Inc (NASDAQ: UBX ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) (went public Friday) Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN ) (went public Friday) Lantern Pharma Inc. (NASDAQ: LTRN ) Nkarta Inc (NASDAQ: NKTX ) Recro Pharma Inc (NASDAQ: REPH ) (reacted to second-quarter results) Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease.
   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   41 Stocks Moving in Tuesday's Pre-Market Session  2020/11/17 11:59:06 Benzinga
Gainers Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares rose 62.8% to $2.10 in pre-market trading as the company disclosed that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 31.6% to $2.21 in pre-market trading after the company’s 10% owner Bradford T Whitmore reported the purchase of 62,000 shares at an average price of $1.69 per share. Yunhong CTI Ltd. (NASDAQ: CTIB ) rose 27.1% to $2.30 in pre-market trading. Sequential Brands Group, Inc. (NASDAQ: SQBG ) rose 23.4% to $8.70 in pre-market trading after the company swung to a profit in the third quarter. Sequans Communications S.A. (NYSE: SQNS ) rose 15.8% to $5.34 in pre-market trading after gaining around 5% on Monday. Golden Bull Limited (NASDAQ: BTBT ) rose 13.5% to $6.14 in pre-market trading after jumping 25% on Monday. Tesla, Inc. (NASDAQ: TSLA ) rose 11.8% to $456.14 in pre-market trading. Tesla will be added to the S&P 500 index after months and months of speculation.
   Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update  2020/11/10 21:05:00 GlobeNewswire
- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2…
   Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Buy at Zacks Investment Research  2020/10/22 05:14:48 Zolmax News
Clearside Biomedical (NASDAQ:CLSD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $1.75 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 22.38% from the company’s current price. According to Zacks, […]
   The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September  2020/08/11 12:20:27 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical readout) Silk Road Medical Inc (NASDAQ: SILK ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) (announced FDA nod for pain drug) Unity Biotechnology Inc (NASDAQ: UBX ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) (went public Friday) Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN ) (went public Friday) Lantern Pharma Inc. (NASDAQ: LTRN ) Nkarta Inc (NASDAQ: NKTX ) Recro Pharma Inc (NASDAQ: REPH ) (reacted to second-quarter results) Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease.
   41 Stocks Moving in Tuesday's Pre-Market Session  2020/11/17 11:59:06 Benzinga
Gainers Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares rose 62.8% to $2.10 in pre-market trading as the company disclosed that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 31.6% to $2.21 in pre-market trading after the company’s 10% owner Bradford T Whitmore reported the purchase of 62,000 shares at an average price of $1.69 per share. Yunhong CTI Ltd. (NASDAQ: CTIB ) rose 27.1% to $2.30 in pre-market trading. Sequential Brands Group, Inc. (NASDAQ: SQBG ) rose 23.4% to $8.70 in pre-market trading after the company swung to a profit in the third quarter. Sequans Communications S.A. (NYSE: SQNS ) rose 15.8% to $5.34 in pre-market trading after gaining around 5% on Monday. Golden Bull Limited (NASDAQ: BTBT ) rose 13.5% to $6.14 in pre-market trading after jumping 25% on Monday. Tesla, Inc. (NASDAQ: TSLA ) rose 11.8% to $456.14 in pre-market trading. Tesla will be added to the S&P 500 index after months and months of speculation.
   Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update  2020/11/10 21:05:00 GlobeNewswire
- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2…
   Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Buy at Zacks Investment Research  2020/10/22 05:14:48 Zolmax News
Clearside Biomedical (NASDAQ:CLSD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $1.75 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 22.38% from the company’s current price. According to Zacks, […]
   The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September  2020/08/11 12:20:27 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical readout) Silk Road Medical Inc (NASDAQ: SILK ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) (announced FDA nod for pain drug) Unity Biotechnology Inc (NASDAQ: UBX ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) (went public Friday) Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN ) (went public Friday) Lantern Pharma Inc. (NASDAQ: LTRN ) Nkarta Inc (NASDAQ: NKTX ) Recro Pharma Inc (NASDAQ: REPH ) (reacted to second-quarter results) Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease.
   Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update  2020/08/10 20:05:00 GlobeNewswire
- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) -- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クリアサイド・バイオメディカル CLSD Clearside Biomedical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)